Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Pieris Pharmaceuticals Inc (PIRS)

Pieris Pharmaceuticals Inc (PIRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Pieris Pharmaceuticals: Q1 Earnings Snapshot

Pieris Pharmaceuticals: Q1 Earnings Snapshot

PIRS : 8.68 (+1.28%)
Pieris Pharmaceuticals: Q3 Earnings Snapshot

Pieris Pharmaceuticals: Q3 Earnings Snapshot

PIRS : 8.68 (+1.28%)
Pieris Pharmaceuticals: Q1 Earnings Snapshot

Pieris Pharmaceuticals: Q1 Earnings Snapshot

PIRS : 8.68 (+1.28%)
Pieris Pharmaceuticals: Q3 Earnings Snapshot

Pieris Pharmaceuticals: Q3 Earnings Snapshot

PIRS : 8.68 (+1.28%)
Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference

BOSTON, MA / ACCESSWIRE / June 2, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology...

PIRS : 8.68 (+1.28%)
Chau Khuong Joins Catalio Capital Management as General Partner

Catalio Capital Management, LP (“Catalio”), a leading multi-strategy life sciences investment firm, today announced that Chau Khuong, who was most recently a Partner at OrbiMed Advisors, has joined...

FUSN : 21.55 (+0.14%)
GKOS : 119.29 (+0.26%)
NTLA : 22.95 (+3.61%)
ICPT : 19.00 (+0.21%)
INSP : 133.94 (-0.23%)
NXTC : 1.5700 (+4.67%)
PIRS : 8.68 (+1.28%)
Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference

BOSTON, MA / ACCESSWIRE / May 18, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology...

PIRS : 8.68 (+1.28%)
Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Company To Host an Investor Conference Call On Wednesday, May 11, 2022 At 8:00 Am EDT BOSTON, MA / ACCESSWIRE / May 11, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology...

PIRS : 8.68 (+1.28%)
Pieris Pharmaceuticals To Host First Quarter 2022 Investor Call and Provide Corporate Update on May 11, 2022

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

PIRS : 8.68 (+1.28%)
3 Risky Stocks With Huge Potential Upside

Why risk-tolerant investors want to own Shopify, Silvergate Capital, and Pieris Pharmaceuticals.

PIRS : 8.68 (+1.28%)
SI : 1.2500 (+0.81%)
SHOP : 66.73 (+1.01%)
AMZN : 197.59 (-1.21%)
NVAX : 12.55 (-3.24%)
AZN : 76.80 (-0.25%)
SGEN : 228.74 (-0.07%)

Barchart Exclusives

3 Mid-Cap Energy Dividend Stocks to Scoop Up Now
Amid predictions of higher oil prices, here are three dividend-paying energy stocks that are worth adding to your portfolio. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar